Versartis’ research and development efforts are focused on orphan endocrine diseases for which improved treatment approaches are needed.
The company’s lead candidate, somavaratan (VRS-317), is a novel, long-acting form of recombinant human growth hormone. Somavaratan is currently in Phase 3 clinical trials for the treatment of pediatric growth hormone deficiency (GHD) and a Phase 2 clinical trial for the treatment of adult GHD.
Current and future research efforts are focused on areas of unmet patient need in endocrine diseases. Contact us directly to discuss partnership opportunities.
- Yuen, et al. J Clin Endocinol Metab, June 2013, 98 (6): 2595-2603.
- Versartis Long-Acting Growth Hormone in Children Compared To Daily rhGH (VELOCITY). https://clinicaltrials.gov/ct2/show/NCT02339090
- Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (VRS-317). https://clinicaltrials.gov/ct2/show/NCT02413138
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD. https://clinicaltrials.gov/ct2/show/NCT02719990